贝那普利、厄贝沙坦联合阿托伐他汀治疗早期糖尿病肾病的临床疗效观察.docVIP

精品论文 参考文献 贝那普利、厄贝沙坦联合阿托伐他汀治疗早期糖尿病肾病的临床疗效观察 王艳 淡雪川（通讯作者） 　　（四川省宜宾市第二人民医院南区内科 四川宜宾 644000） 　　【摘要】　目的 观察贝那普利、厄贝沙坦联合阿托伐他汀在治疗早期糖尿病肾病患者中的疗效。方法 选取我科住院的糖尿病肾病患者85例，随机分成3组，A组（贝那普利组10mg/d）27例，B组（贝那普利10mg/d +厄贝沙坦组150 mg/d）23例，C组（贝那普利10mg/d +厄贝沙坦150 mg/d +阿托伐他汀组10 mg/d）35例，全部病例连续治疗12周后，观察患者治疗前后血压、血清胆固醇（TC）、甘油三酯（TG）、血清内生肌酐清除率（Ccr）及24h尿微量白蛋白定量以及治疗后三组间上述各项指标。结果 3组患者治疗后收缩压、舒张压及平均动脉压(MAP)较治疗前均有明显降低，差异有统计学意义(Plt;0．01)， B组、C组治疗后收缩压、舒张压和MAP与A组比较有明显降低（Plt;0．05）。C组治疗后TC、TG较治疗前有显著下降（p＜0.05），3组患者治疗后血清内生肌酐清除率（Ccr）及24h尿微量白蛋白定量均较治疗前有明显改善（p＜0.05），其中C组治疗后血清内生肌酐清除率（Ccr）及24h尿白微量蛋白定量较其他2组也有显著差异（p＜0.05）。结论 贝那普利、厄贝沙坦和阿托伐他汀联合应用可明显降低血压、血脂及显著改善血清内生肌酐清除率和尿蛋白排泄率。 　　【关键词】贝那普利 厄贝沙坦 阿托伐他汀 糖尿病 肾病 　　【中图分类号】R453 【文献标识码】A 【文章编号】1672-5085（2014）10-0066-02 　　The clinical effect analysis of Benazepril combined with Irbesartan and Atorvastatin in the treatment of early diabetic nephropathy 　　Wang Yan,Dan Xue Chuan 　　（The southern department of internal medicine ,the Second Peoplersquo;s Hospital of Yibin, Yibin 644000） 　　【Abstract】Objective To investigate the clinical efficacy of Benazepril combined with Irbesartan and Atorvastatin in the treatment of early diabetic nephropathy(DN). Methods 85 patients of diabetic nephropathy(DN) in our hospital were randomly divided into three groups: group A (Benazepril 10mg/d n=27), group B (Benazepril 10mg/d+ Irbesartan 150 mg/d n=23), group C (Benazepril 10mg/d+ Irbesartan 150 mg/d+ Atorvastatin 10 mg/d n=35). BP,TC, TG, the level of Ccr and 24h urinary microalbumin were statistically analyzed before and after 12 weeks treatment. Results Systolic blood pressure（SBP） 、diastolic blood pressure（DBP） and mean arterial blood pressure（MAP）after treatment in the three groups were significantly lower than those before treatment（p＜0.05）. SBP, DBP and MAP in group B and group C after treatment were lower than those in group A（p＜0.05）. After 12 weeks treatment, The levels of TC,TG in group C were decreased significantly（